QuVa Pharma Announces Availability of Sodium Bicarbonate Syringe

Compounded Sodium Bicarbonate PF 8.4% 50mEq per syringe is expected to help alleviate chronic drug shortage impacting the nation’s hospitals.

It has been widely reported in the national press, including US Today, Modern Healthcare, and the New York Times, that there is a nation-wide shortage of pharmaceutical quality sodium bicarbonate available to hospitals. A shortage of the antacid is prompting healthcare providers to carefully prioritize procedures, delay some operations or choose alternative treatments. This shortage is expected to persist to some degree for a number of months.

QuVa Pharma, Inc. is pleased to advise that it has supplies of Sodium Bicarbonate PF 8.4% (1mEq/ml) 50ml in a syringe (50mEq per syringe) available. QuVa is currently supplying this product to existing customers and welcomes new enquiries.

With deep aseptic pharmaceutical manufacturing experience, QuVa specializes in critical drug shortage products. The sodium bicarbonate compounded by QuVa is sourced from a USA made and FDA approved manufacturer, and joins a range of critical shortage products including Calcium Chloride, Potassium Phosphate, and Rocuronium all compounded from FDA approved starting material. All product sold is accompanied by a Certificate of Analysis verifying sterility, and product specifications.

“It is important in times of drug shortage that we are able to offer high quality solutions for our customers and provide reliable, pertinent, and cost-effective product for them to continue quality care to their patients,” said Stuart Hinchen, QuVa Pharma’s co-founder and Chief Executive Officer. “We are able to maintain the industry leading quality standards of our products by only sourcing product from FDA approved suppliers of the starting material. This lifts the burden off the hospitals to find their own solutions without the same level of supplier knowledge and product development controls that we have. Patients need solutions in drug shortage situations, and we aim to be there for them.”

QuVa is the market leader in quality compliance with both existing Texas facilities in excellent standing with the FDA, having received the Inspection Close out report in March 2017 for the main Sugar Land, Texas campus. QuVa is opening the first phase of its 160,000 sq ft New Jersey facility in July 2017, with further expansion at that site on schedule for commissioning in Q4 2017.

For product ordering inquiries please contact QuVa Customer Service at 888.339.0874 or via email at customer.service@quvapharma.com

About QuVa Pharma, Inc.
QuVa Pharma is a nationally recognized company emerging as the leading industry 503B platform and partner of choice for compliance-oriented healthcare facilities looking to ensure a quality, safe and consistent supply of medications. The Company offers a broad portfolio of products across Pain Management, Anti-effective, OR Syringes, Labor and Delivery therapeutic areas amongst others, all of which are released only once sterility and potency testing is successfully complete, and with validation supporting appropriate BUD. The company is committed to having a patient-first orientation, as well as a robust product portfolio, leading safety standards, and collaborative, partnership-oriented customer service. For more information, visit www.quvapharma.com